20/20 BioLabs Q2 revenue up 37% to $0.7M; OneTest revenue up 47%

20/20 Biolabs, Inc.

2026-Q2 EPS reported -$0.54 revenue$1,083,946

Q2 2026 total revenue $0.7M, up 36.5% YoY; OneTest revenue $0.7M, up 47.1%, 95.3% of total.
Gross profit $0.3M, up 86.6%; gross margin 41.7% vs 30.5%.
Net loss $1.5M vs $0.8M; cash $4.5M, up from $1.0M; convertible note debt eliminated.
Vermont and Maryland firefighter programs expected to generate >$1.0M revenue through 2026; >35,000 firefighters tested by year-end.
Raised $6.0M Series E preferred in H1 2026; up to $40M available; standstill with Streeterville.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.